| Year |
Citation |
Score |
| 2023 |
Canella A, Nazzaro M, Rajendran S, Schmitt C, Haffey A, Nigita G, Thomas D, Lyberger JM, Behbehani GK, Amankulor NM, Mardis ER, Cripe TP, Rajappa P. Genetically modified IL2 bone-marrow-derived myeloid cells reprogram the glioma immunosuppressive tumor microenvironment. Cell Reports. 42: 112891. PMID 37516967 DOI: 10.1016/j.celrep.2023.112891 |
0.376 |
|
| 2020 |
Tang B, Guo ZS, Bartlett DL, Yan DZ, Schane CP, Liu J, McFadden G, Thomas DL, Shisler JL, Roy EJ. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32019860 DOI: 10.1158/1078-0432.Ccr-18-3626 |
0.619 |
|
| 2019 |
Misiolek KA, Osborn ZG, Hauser N, Thomas D, Goodman JF, Fulkerson DH. Rapidly growing, multifocal, benign choroid plexus tumor in an infant: case report. Journal of Neurosurgery. Pediatrics. 1-6. PMID 30797210 DOI: 10.3171/2018.12.Peds18453 |
0.359 |
|
| 2017 |
Thomas DL, Manners J, Marker D, Mettenburg J, Murdoch G, Stevens B, Wang G, Wiley C. CD8-Positive T-Cell Leukoencephalitis With Astrocytopathy Clinically Presenting as Neuromyelitis Optica. Journal of Neuropathology and Experimental Neurology. PMID 28340257 DOI: 10.1093/Jnen/Nlx015 |
0.314 |
|
| 2014 |
Tosic V, Thomas DL, Kranz DM, Liu J, McFadden G, Shisler JL, MacNeill AL, Roy EJ. Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity. Plos One. 9: e109801. PMID 25329832 DOI: 10.1371/Journal.Pone.0109801 |
0.636 |
|
| 2013 |
Tosic V, Thomas DL, Kranz DM, Liu J, McFadden G, MacNeill AL, Roy EJ. Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-P137 |
0.632 |
|
| 2012 |
West DC, Qin Y, Peterson QP, Thomas DL, Palchaudhuri R, Morrison KC, Lucas PW, Palmer AE, Fan TM, Hergenrother PJ. Differential effects of procaspase-3 activating compounds in the induction of cancer cell death. Molecular Pharmaceutics. 9: 1425-34. PMID 22486564 DOI: 10.1021/Mp200673N |
0.529 |
|
| 2011 |
Thomas DL, Doty R, Tosic V, Liu J, Kranz DM, McFadden G, Macneill AL, Roy EJ. Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors. Cancer Immunology, Immunotherapy : Cii. 60: 1461-72. PMID 21656158 DOI: 10.1007/S00262-011-1045-Z |
0.661 |
|
| 2011 |
France MR, Thomas DL, Liu J, McFadden G, MacNeill AL, Roy EJ. Intraventricular injection of myxoma virus results in transient expression of viral protein in mouse brain ependymal and subventricular cells. The Journal of General Virology. 92: 195-9. PMID 20861319 DOI: 10.1099/Vir.0.026690-0 |
0.605 |
|
| 2009 |
Thomas DL, Kim M, Bowerman NA, Narayanan S, Kranz DM, Schreiber H, Roy EJ. Recurrence of intracranial tumors following adoptive T cell therapy can be prevented by direct and indirect killing aided by high levels of tumor antigen cross-presented on stromal cells. Journal of Immunology (Baltimore, Md. : 1950). 183: 1828-37. PMID 19592642 DOI: 10.4049/Jimmunol.0802322 |
0.642 |
|
| 2008 |
Thomas DL, Kranz DM, Roy EJ. Experimental manipulations of afferent immune responses influence efferent immune responses to brain tumors. Cancer Immunology, Immunotherapy : Cii. 57: 1323-33. PMID 18278494 DOI: 10.1007/S00262-008-0467-8 |
0.618 |
|
| 2005 |
Roy EJ, Takikawa O, Kranz DM, Brown AR, Thomas DL. Neuronal localization of indoleamine 2,3-dioxygenase in mice. Neuroscience Letters. 387: 95-9. PMID 16076525 DOI: 10.1016/J.Neulet.2005.07.010 |
0.532 |
|
| Show low-probability matches. |